22/10/2010
MRIs May Lead To Unnecessary Breast Surgery
Women could be undergoing unnecessary breast surgery as a result of having magnetic resonance imaging (MRI), says an expert on bmj.com today.
Malcolm Kell, Consultant Surgeon and Senior Lecturer at the Eccles Breast Screening Unit at University College Dublin, said in the last decade MRI or magnetic resonance mammography (MRM) has become the most favoured type of investigation for high risk patients when combined with mammography and ultrasound.
He added MRM is extremely useful in monitoring advanced breast cancer and also to assess the response in the breast following chemotherapy, however the use of this technology in early stage breast cancer may do more harm than good.
He concluded that “there is no compelling evidence that this technique should be routinely used in newly diagnosed breast cancer.”
The author refers to one study in women with breast cancer who were being considered for treatment without surgery which shows a 6% increase for mastectomies in women who had an MRM compared to women who did not. He believes the higher rates of surgery could be because MRM is so sophisticated that it picks up harmless recurrence or extension of tumours whose removal will not alter the patient's prognosis.
While supporters of MRM say using it routinely is likely to pick up disease recurrence, the evidence does not back up their view, says Kell.
He argues that the best way to manage early stage breast cancer and reduce the need for unnecessary and invasive surgery is through yearly monitoring and drug treatment and radiotherapy where necessary.
(BMcN/GK)
Malcolm Kell, Consultant Surgeon and Senior Lecturer at the Eccles Breast Screening Unit at University College Dublin, said in the last decade MRI or magnetic resonance mammography (MRM) has become the most favoured type of investigation for high risk patients when combined with mammography and ultrasound.
He added MRM is extremely useful in monitoring advanced breast cancer and also to assess the response in the breast following chemotherapy, however the use of this technology in early stage breast cancer may do more harm than good.
He concluded that “there is no compelling evidence that this technique should be routinely used in newly diagnosed breast cancer.”
The author refers to one study in women with breast cancer who were being considered for treatment without surgery which shows a 6% increase for mastectomies in women who had an MRM compared to women who did not. He believes the higher rates of surgery could be because MRM is so sophisticated that it picks up harmless recurrence or extension of tumours whose removal will not alter the patient's prognosis.
While supporters of MRM say using it routinely is likely to pick up disease recurrence, the evidence does not back up their view, says Kell.
He argues that the best way to manage early stage breast cancer and reduce the need for unnecessary and invasive surgery is through yearly monitoring and drug treatment and radiotherapy where necessary.
(BMcN/GK)
Related UK National News Stories
Click here for the latest headlines.
12 April 2006
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
20 September 2011
Short Cut To Breast Surgery Welcomed
An innovative new approach to breast surgery that allows women with breast cancer to return home on the same day as their surgery has been praised by the Deputy Prime Minister Nick Clegg.
Short Cut To Breast Surgery Welcomed
An innovative new approach to breast surgery that allows women with breast cancer to return home on the same day as their surgery has been praised by the Deputy Prime Minister Nick Clegg.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
08 August 2014
NICE Criticises Cost Of New Breast Cancer Drug
NICE, the NHS drugs advisory body, has advised that a new breast cancer treatment not be routinely used in England. The National Institute for Health and Care Excellence (NICE) has criticised the drugs manufacturer, Roche, over the price of the drug – Kadcyla. It is understood that the treatment costs approximately £90,000 per patient.
NICE Criticises Cost Of New Breast Cancer Drug
NICE, the NHS drugs advisory body, has advised that a new breast cancer treatment not be routinely used in England. The National Institute for Health and Care Excellence (NICE) has criticised the drugs manufacturer, Roche, over the price of the drug – Kadcyla. It is understood that the treatment costs approximately £90,000 per patient.
23 April 2014
Nice To Block New Breast Cancer Drug
The National Institute for Health and Care Excellence (Nice) is moving to block a new breast cancer drug because it said it is not effective enough to justify the price the NHS is being asked to pay. The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.
Nice To Block New Breast Cancer Drug
The National Institute for Health and Care Excellence (Nice) is moving to block a new breast cancer drug because it said it is not effective enough to justify the price the NHS is being asked to pay. The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.